{"_id":{"$oid":"5c6be224534d89680d12ddb3"},"created_at":{"$date":"2019-02-19T11:01:56.841Z"},"updated_at":{"$date":"2019-02-19T11:01:56.841Z"},"name":"Module1","course_id":{"$oid":"5c6bd5f9acafad5e5f856dfe"},"content":"\u003cp\u003eHistory \u0026amp; Introduction:\u003c/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eWilllian Withering FRS \u003c/strong\u003e (17 March 1741 \u0026ndash; 6 October 1799).\u003c/p\u003e\n\n\u003cp\u003eHe has written a book \u0026ldquo;An Account of the\u003c/p\u003e\n\n\u003cp\u003eFoxglove and Some of its Medicinal Uses: With\u003c/p\u003e\n\n\u003cp\u003ePractical Remarks on Dropsy and Other Diseases\u0026rdquo;.\u003c/p\u003e\n\n\u003cp\u003eExplained the events developed after the large doses of foxglove (source of digoxin).\u003c/p\u003e\n\n\u003cp\u003eThe alarming sign for the regulations of drugs:\u003c/p\u003e\n\n\u003cp\u003eThalidomide disaster.\u003c/p\u003e\n\n\u003cp\u003eThalidomide drug is given for nausea in pregnancy and lead to thousands of children born with deformity limbs (Phocomelia-seal like limbs)\u003c/p\u003e\n\n\u003cul\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003e1961-Dr. McBride, an Australian doctor, wrote a letter to the editor of the Lancet Journal, in which he suggested a connection between congenital malformation of babies and thalidomide.\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eDr. Lenz - German Pediatrician- Suggested a co-relation of thalidomide and congenital anomalies and published an article.\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eDr. Frances Oldham Kelsey - Pharmacologist and a Physician- The women who struggled\u0026nbsp;hard for thalidomide not to enter into USA market .\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eThe sulfanilamide tragedy:\u003c/p\u003e\n\n\u003cp\u003e1937:\u003c/p\u003e\n\n\u003cul\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eThe medicine sulphanilamide was prepared as tablets and capsules from pharmaceutical companies and the S.E. Massengill Company of Bristol, Tennessee, decided that a liquid form of sulphanilamide be prepared with composition of 10 percent sulfanilamide, 72 percent diethylene glycol, and 16 percent water.\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eThe composition lead to nearly 107 deaths in the USA, because of the use of sulfanilamide elixir, containing diethyl glycol as the solvent.\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003e1938:\u003c/p\u003e\n\n\u003cul\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eThe incident triggered the Food, Drugs and cosmetic act to monitor the safety of new drugs.\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003e1962- USA, Approved an amendment requiring safety and efficacy data of drugs before premarketing submission.\u003c/p\u003e\n\n\u003cp\u003eThis is called as \u0026ldquo;Kafauver Haris Amendment\u0026rdquo;\u003c/p\u003e\n\n\u003cp\u003eInformed consent was required \u0026amp; Adverse drug reaction was required to report FDA.\u003c/p\u003e\n\n\u003cp\u003e1962: Yellow card Scheme was developed by Bill Inman after Thalidomide disaster.\u003c/p\u003e\n\n\u003cp\u003eAdverse reactions are to be reported according to the scheme. It is organized by Medicines and Health care Products Regulatory Agency (MHRA).\u003c/p\u003e\n\n\u003cp\u003eYellow cards are available from pharmacies and a few are in the British National Formulary as tear off pages.\u003c/p\u003e\n\n\u003cp\u003e1965: First Pharmaceutical directive 65/65/EC.\u003c/p\u003e\n\n\u003cp\u003eEuropean legislation developed . European Law requires all medicinal products to obtain a Marketing Authorisation before they are in the EU market.\u003c/p\u003e\n\n\u003cp\u003e\u003cstrong\u003e1966- pilot study of Boston Collaborative Drug Surveillance Program started.\u003c/strong\u003e\u003c/p\u003e\n\n\u003cp\u003eIt was the first group to conduct epidemiologic researches to quantify the potential adverse effects of drugs utilizing in-hospital monitoring and had an essential role in the development and application of methods in drug epidemiology.\u003c/p\u003e\n\n\u003cp\u003e\u003cbr /\u003e\n\u0026nbsp;\u003c/p\u003e\n\n\u003cp\u003e1968-the WHO Programme for International Drug Monitoring was instituted.\u003c/p\u003e\n\n\u003cp\u003eDuring the 16th World assembly there was a call for \u0026ldquo;Systematic collection of adverse drug reactions, once the drug is marketed. ten members participated in this program (Australia, UK, USA, Germany, Canada, Ireland, Sweden, Denmark, New Zealand, and Netherlands).\u003c/p\u003e\n\n\u003cp\u003e1992- the European Society of Pharmacovigilance (ESoP) was established and changed into the International Society of Pharmacovigilance (IsoP).\u003c/p\u003e\n\n\u003cp\u003eESoP- International non profit scientific organization- it strengths the Pharmacovigilance and enhance for safe and proper use of medicines.\u003c/p\u003e\n\n\u003cp\u003eLatet ESoP is changed to ISoP.\u003c/p\u003e\n\n\u003cp\u003e\u003cbr /\u003e\n\u0026nbsp;\u003c/p\u003e\n\n\u003cp\u003e1995- the European Medicines Agency (EMA) was set up.\u003c/p\u003e\n\n\u003cp\u003eThe main aim of EMA is to harmonize the work between the national medicine regulatory bodies.\u003c/p\u003e\n\n\u003cp\u003eOver the course of time EMA has developed regulations to Rare diseases, herbal medicines, herbal medicines and advanced therapy medicines.\u003c/p\u003e\n\n\u003cp\u003e\u003cbr /\u003e\n\u0026nbsp;\u003c/p\u003e\n\n\u003cp\u003e2001-EudraVigilance came into existence.\u003c/p\u003e\n\n\u003cp\u003eIt is the official European database for managing and analysing information on suspected adverse reactions to medicines which have been authorized for the market or being studied in European clinical trials.\u003c/p\u003e\n\n\u003cp\u003e\u003cbr /\u003e\n\u0026nbsp;\u003c/p\u003e\n\n\u003cp\u003e2001-EudraVigilance came into existence.\u003c/p\u003e\n\n\u003cp\u003eIt is the official European database for managing and analysing information on suspected adverse reactions to medicines which have been authorized for the market or being studied in European clinical trials.\u003c/p\u003e\n\n\u003cp\u003e2012- New legislation in European pharmacovigilance (Directive 2010/84/EU).\u003c/p\u003e\n\n\u003cp\u003eThe pharmacovigilance is further amended in order to strengthen the patient safety and well being.\u003c/p\u003e\n\n\u003cp\u003eThe Good Pharmacovigilance practices came into existence.\u003c/p\u003e\n\n\u003cp\u003e2017- The new EudraVigilance format was launched.\u003c/p\u003e\n\n\u003cp\u003eThe updated Pharmacovigilance legislation had significant changes in electronic reporting for suspected adverse drug reactions which supports better safety monitoring of drugs and more efficient system for stakeholders.\u003c/p\u003e\n","__v":0}
{"_id":{"$oid":"5c6be569534d89680d12ddb4"},"created_at":{"$date":"2019-02-19T11:15:53.868Z"},"updated_at":{"$date":"2019-02-19T11:15:53.868Z"},"name":"Module2","course_id":{"$oid":"5c6bd5f9acafad5e5f856dfe"},"content":"\u003cp\u003e\u003cstrong\u003eThe need of Pharmacovigilance\u003c/strong\u003e\u003c/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eIntroduction:\u003c/strong\u003e\u003c/p\u003e\n\n\u003cul\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eThe treatment of diseases changed a lot with the help of modern medicines.\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eHowever, despite all their benefits, evidence continues to mount that adverse reactions to medicines are a common, yet often preventable, cause of illness, disability and even death.\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eIt\u0026rsquo;s the time to:\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;a.prevent or reduce harm to patients and thus improve public health and safety.\u003c/p\u003e\n\n\u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;b.Evaluate the harm and monitor the safety of medicines in clinical use.\u003c/p\u003e\n\n\u003cp\u003eDefinition:\u003c/p\u003e\n\n\u003cp\u003e\u0026ldquo;Pharmacovigilance is defined as the science and activities related to the detection, assessment, understanding and prevention of adverse effects or any other drug related- problem\u0026rdquo;.\u003c/p\u003e\n\n\u003cp\u003e\u0026ldquo;\u003cem\u003eThis applies throughout the life cycle of a medicine equally to \u003c/em\u003e\u003c/p\u003e\n\n\u003cp\u003e\u003cem\u003ethe pre-approval stage as to the post-approval.\u0026rdquo;\u003c/em\u003e\u003c/p\u003e\n\n\u003cp\u003eThe Pharmacovigilance not only includes the modern medicines, but it also extended to Herbals, traditional and complementary medicines, blood products, biologicals, medical devices, vaccines.\u003c/p\u003e\n\n\u003cp\u003eIt involves many other issues:\u003c/p\u003e\n\n\u003cul\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eSubstandard medicines,\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003emedication errors,\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003elack of efficacy reports,\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003euse of medicines for indications that are not approved and for which there is inadequate scientific basis,\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003ecase reports of acute and chronic poisoning,\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eassessment of drug-related mortality,\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eabuse and misuse of medicines,\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eadverse interactions of medicines with chemicals, other medicines, and food.\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eLife cycle of a drug:\u003c/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eBrief description of clinical trials\u003c/strong\u003e\u003cstrong\u003e:\u003c/strong\u003e\u003c/p\u003e\n\n\u003col\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003e\u003cstrong\u003ePreclinical Studies:\u003c/strong\u003e\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u003c/ol\u003e\n\n\u003cp\u003e\u003cstrong\u003eAnimal studies tested for \u003c/strong\u003e\u003c/p\u003e\n\n\u003cul\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eAcute toxicity\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eOrgan damage,\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003ePharmacokinetics\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eCarcinogenicity\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eMutagenicity\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003col\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003e\u003cstrong\u003ePhase- I\u003c/strong\u003e\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u003c/ol\u003e\n\n\u003cul\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eHealthy volunteers\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eLimited number of subjects\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003e20-50 subjects\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003col\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003e\u003cstrong\u003ePhase- II\u003c/strong\u003e\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u003c/ol\u003e\n\n\u003cul\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003e150-350 subjects with disease.\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eNo healthy volunteers.\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eControlled study only\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003col\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003e\u003cstrong\u003ePhase-III\u003c/strong\u003e\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u003c/ol\u003e\n\n\u003cul\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003e250-4000 subjects with disease\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eLarge number of general population\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003e\u003cbr /\u003e\n\u0026nbsp;\u003c/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eWhy Pharmacovigilance?\u003c/strong\u003e\u003c/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eReason 1: \u003c/strong\u003e\u003c/p\u003e\n\n\u003cul\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eHumanitarian grounds \u0026ndash;\u003c/p\u003e\n\n\u0009\u003col\u003e\n\u0009\u0009\u003cli\u003e\n\u0009\u0009\u003cp\u003eInsufficient evidence of safety from clinical trials\u003c/p\u003e\n\u0009\u0009\u003c/li\u003e\n\u0009\u0009\u003cli\u003e\n\u0009\u0009\u003cp\u003eAnimal experiments\u003c/p\u003e\n\u0009\u0009\u003c/li\u003e\n\u0009\u0009\u003cli\u003e\n\u0009\u0009\u003cp\u003ePhase 1 \u0026ndash; 3 studies prior to marketing authorization\u003c/p\u003e\n\u0009\u0009\u003c/li\u003e\n\u0009\u003c/ol\u003e\n\u0009\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eLimitations in Clinical trials:\u003c/p\u003e\n\n\u003cul\u003e\n\u0009\u003cli\u003e\n\u0009\u003col\u003e\n\u0009\u0009\u003cli\u003e\n\u0009\u0009\u003cp\u003eLimited size: no more than 5000 and often as little as 500 volunteers\u003c/p\u003e\n\u0009\u0009\u003c/li\u003e\n\u0009\u0009\u003cli\u003e\n\u0009\u0009\u003cp\u003eNarrow population: age and sex specific\u003c/p\u003e\n\u0009\u0009\u003c/li\u003e\n\u0009\u0009\u003cli\u003e\n\u0009\u0009\u003cp\u003eNarrow indications: only the specific disease studied\u003c/p\u003e\n\u0009\u0009\u003c/li\u003e\n\u0009\u0009\u003cli\u003e\n\u0009\u0009\u003cp\u003eShort duration: often no longer than a few weeks\u003c/p\u003e\n\u0009\u0009\u003c/li\u003e\n\u0009\u003c/ol\u003e\n\u0009\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eReason 2\u003c/strong\u003e\u003c/p\u003e\n\n\u003cul\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eMedicines are supposed to save lives\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\n\u003cp\u003e\u003cem\u003eDying from a disease is sometimes unavoidable; dying from a medicine is unacceptable. \u003c/em\u003e\u003c/p\u003e\n\n\u003cp\u003e\u003cem\u003eLepakhin V. Geneva 2005\u003c/em\u003e\u003c/p\u003e\n\n\u003cp\u003eUK:\u003c/p\u003e\n\n\u003cp\u003e\u003cspan dir=\"ltr\"\u003eIt has been suggested that ADRs may cause 5700 deaths per year in UK.\u003c/span\u003e\u003c/p\u003e\n\n\u003cp\u003e\u003cspan dir=\"ltr\"\u003e\u003cem\u003ePirmohamed et al, 2004\u003c/em\u003e\u003c/span\u003e\u003c/p\u003e\n\n\u003cp\u003eUS:\u003c/p\u003e\n\n\u003cp\u003e\u003cspan dir=\"ltr\"\u003eADRs were 4th-6th commonest cause of death in the US in 1994\u003c/span\u003e\u003c/p\u003e\n\n\u003cp\u003e\u003cspan dir=\"ltr\"\u003e\u003cem\u003eLazarou et al, 1998\u003c/em\u003e\u003c/span\u003e\u003c/p\u003e\n\n\u003cp\u003e\u003cimg src=\"data:image/png;base64,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\" style=\"height:175px; width:624px\" /\u003e\u003c/p\u003e\n\n\u003cul\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003e125 Patients\u003c/p\u003e\n\n\u0009\u003cp\u003e\u003cspan dir=\"ltr\"\u003e(59%) were\u003cstrong\u003e \u003c/strong\u003eavoidable\u003c/span\u003e\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003e24 Patients experienced ADRs (19%)\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eReason 3: \u003c/strong\u003e\u003c/p\u003e\n\n\u003cul\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003e\u003cstrong\u003eADRs are expensive!!\u003c/strong\u003e\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003e\u003cimg src=\"data:image/png;base64,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\" style=\"height:174px; width:624px\" /\u003e\u003c/p\u003e\n\n\u003cul\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003e6.5% of admissions are due to ADRs\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eSeven 800-bed hospitals are occupied by ADR patients\u003c/p\u003e\n\n\u0009\u003cp\u003e\u003cspan dir=\"ltr\"\u003eCost \u0026pound;446 million per annum\u003c/span\u003e\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eCost of drug related morbidity and mortality exceeded $177.4 billion in 2000\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003e(\u003cem\u003eErnst FR \u0026amp; Grizzle AJ, 2001: J American Pharm. Assoc)\u003c/em\u003e\u003c/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eReason 4:\u003c/strong\u003e\u003c/p\u003e\n\n\u003cp\u003ePromoting rational use of medicines and adherence\u003c/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eReason 5: \u003c/strong\u003e\u003c/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eEnsuring public confidence\u003c/strong\u003e\u003c/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eReason 6: \u003c/strong\u003eEthics\u003c/p\u003e\n\n\u003cp\u003eTo know of something that is harmful to another person who does not know, and not telling, is unethical.\u003c/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eExamples of product recalls due to toxicity\u003c/strong\u003e\u003c/p\u003e\n\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\n\u003ctable border=\"1\" style=\"width:575px\"\u003e\n\u0009\u003ctbody\u003e\n\u0009\u0009\u003ctr\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003e\u003cstrong\u003eMedicine\u003c/strong\u003e\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003e\u003cstrong\u003eyear\u003c/strong\u003e\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003e\u003cstrong\u003eExamples of serious and unexpected AE leading to withdrawal of medicine\u003c/strong\u003e\u003c/p\u003e\n\n\u0009\u0009\u0009\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u003c/tr\u003e\n\u0009\u0009\u003ctr\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003eThalidomide\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003e1965\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003ePhocomelia\u003c/p\u003e\n\n\u0009\u0009\u0009\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u003c/tr\u003e\n\u0009\u0009\u003ctr\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003ePractolol\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003e1975\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003eSclerosing peritonitis\u003c/p\u003e\n\n\u0009\u0009\u0009\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u003c/tr\u003e\n\u0009\u0009\u003ctr\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003eClioquinol\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003e1970\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003eSubacute nephropathy\u003c/p\u003e\n\n\u0009\u0009\u0009\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u003c/tr\u003e\n\u0009\u0009\u003ctr\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003eBenoxaprofen\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003e1982\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003eNephrotoxicity, cholestatic jaundice\u003c/p\u003e\n\n\u0009\u0009\u0009\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u003c/tr\u003e\n\u0009\u0009\u003ctr\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003eTerfenadine\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003e1997\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003eTorsade de pointes\u003c/p\u003e\n\n\u0009\u0009\u0009\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u003c/tr\u003e\n\u0009\u0009\u003ctr\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003eRofecoxib\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003e2004\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003eCardiovascular effects\u003c/p\u003e\n\n\u0009\u0009\u0009\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u003c/tr\u003e\n\u0009\u0009\u003ctr\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003eVeralipride\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003e2007\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003eAnxiety, depression, movement disorders\u003c/p\u003e\n\n\u0009\u0009\u0009\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u003c/tr\u003e\n\u0009\u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eDrugs and the adverse reactions identified after the drug marketed.\u003c/strong\u003e\u003cbr /\u003e\n\u0026nbsp;\u003c/p\u003e\n\n\u003ctable border=\"1\" style=\"width:623px\"\u003e\n\u0009\u003ctbody\u003e\n\u0009\u0009\u003ctr\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003e\u003cstrong\u003eMedicine\u003c/strong\u003e\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003e\u003cstrong\u003eAdverse reaction\u003c/strong\u003e\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u003c/tr\u003e\n\u0009\u0009\u003ctr\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003e\u003cstrong\u003eAmino phenazone (Amidopyrine)\u003c/strong\u003e\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003e\u003cstrong\u003eAgranulocytosis\u003c/strong\u003e\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u003c/tr\u003e\n\u0009\u0009\u003ctr\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003e\u003cstrong\u003eChloramphenicol\u003c/strong\u003e\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003e\u003cstrong\u003eAplastic anemia\u003c/strong\u003e\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u003c/tr\u003e\n\u0009\u0009\u003ctr\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003e\u003cstrong\u003eClioquinol\u003c/strong\u003e\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003e\u003cstrong\u003eMyelo-optic neuropathy\u003c/strong\u003e\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u003c/tr\u003e\n\u0009\u0009\u003ctr\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003e\u003cstrong\u003eErthromycin estolate\u003c/strong\u003e\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003e\u003cstrong\u003eCholestatic hepatitis\u003c/strong\u003e\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u003c/tr\u003e\n\u0009\u0009\u003ctr\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003e\u003cstrong\u003eFluthane\u003c/strong\u003e\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003e\u003cstrong\u003eHepatocellular hepatitis\u003c/strong\u003e\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u003c/tr\u003e\n\u0009\u0009\u003ctr\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003e\u003cstrong\u003eMethyl dopa\u003c/strong\u003e\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003e\u003cstrong\u003eHemolytic anemia\u003c/strong\u003e\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u003c/tr\u003e\n\u0009\u0009\u003ctr\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003e\u003cstrong\u003eOral contraceptives\u003c/strong\u003e\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003e\u003cstrong\u003eThrombo embolism\u003c/strong\u003e\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u003c/tr\u003e\n\u0009\u0009\u003ctr\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003e\u003cstrong\u003ePractolol\u003c/strong\u003e\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003e\u003cstrong\u003eSclerosing peritonitis\u003c/strong\u003e\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u003c/tr\u003e\n\u0009\u0009\u003ctr\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003e\u003cstrong\u003eReserpine\u003c/strong\u003e\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003e\u003cstrong\u003eDepression\u003c/strong\u003e\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u003c/tr\u003e\n\u0009\u0009\u003ctr\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003e\u003cstrong\u003eStatins\u003c/strong\u003e\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003e\u003cstrong\u003eRhabdomyolysis\u003c/strong\u003e\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u003c/tr\u003e\n\u0009\u0009\u003ctr\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003e\u003cstrong\u003eThalidomide\u003c/strong\u003e\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u0009\u003ctd\u003e\n\u0009\u0009\u0009\u003cp\u003e\u003cstrong\u003eCongenital malformations\u003c/strong\u003e\u003c/p\u003e\n\u0009\u0009\u0009\u003c/td\u003e\n\u0009\u0009\u003c/tr\u003e\n\u0009\u003c/tbody\u003e\n\u003c/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eThe Purpose of Pharmacovigilance system is:\u003c/strong\u003e\u003c/p\u003e\n\n\u003cul\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eCollection of medication related errors.\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eAnalyze the errors\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eEvaluate and implement any further course of action and implement the interventions.\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eProtects and promotes the Public safety\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003ePrevents the preventable errors.\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003e\u003cbr /\u003e\n\u0026nbsp;\u003c/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePharmacovigilance in Europe:\u003c/strong\u003e\u003c/p\u003e\n\n\u003cul\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003ePharmacovigilance system in Europe is coordinated by the European Medicines Agency (EMA) and conducted by the National Competent Authorities (NCAs).\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eThe EMA maintains and develops the pharmacovigilance database comprising all suspected serious adverse drug reactions observed in the European region.\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003ePharmacovigilance in United States\u003c/strong\u003e\u003c/p\u003e\n\n\u003cul\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eIt\u0026rsquo;s a Multifaceted approach in USA.\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eThe US Food and Drug Administration (FDA) receives reports about adverse drug reaction and takes appropriate actions for drug safety.\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eFinally: Am I safe with medicines?\u003c/p\u003e\n","__v":0}
